Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty

November 20, 2013 updated by: Baylis Medical Company

A Randomized, Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty for Treatment of Discogenic Lower Back Pain

Each patient was assigned to one of the two groups: IDB or Sham. On the day of the procedure, an IV was inserted in pre-procedural area and patient transported to the procedure room. The procedure will be completed under fluoroscopy in prone position. Patients were given 1-4 mg of midazolam for relaxation before the procedure and, if needed, 50-100 mcg of fentanyl IV during the procedure. The patients was randomly assigned to treatment or placebo using computer-generated codes maintained in sequentially numbered opaque envelopes. The physician performing procedure was informed of the assignment. In IDB group, guided by the fluoroscopic imaging, two transdiscal probes was positioned in the posterior annulus using a posterolateral, oblique approach. First, two electrically insulated 17G transdiscal introducers was used to gain an access to the disc space. Than, two radiofrequency probes will be positioned through each of the introducers bilaterally to create a bipolar configuration. Placement of the transdiscal probes within the disc annulus will be confirmed using oblique, lateral, and anterior-posterior fluoroscopic images. Sham group had their introducers and electrodes positioned just outside of the disc. This was also be documented using fluoroscopy. Investigator attached the electrodes to inactive heater control device that provide a similar auditory and visual experience for the patient. Patients were therefore remain blinded to actual treatment and physician performing procedure was not involved in patient's follow-up. Patients were awake and communicating with the physician conducting the procedure and if pain in legs were present and increased during the procedure, the heating protocol would be stopped. Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes, then discharged home with instructions. The patients were followed over a period of 12 months.

Study Overview

Detailed Description

Back Pain

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • The Center for Clinical Research
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic Pain Management

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The inclusion criteria will be as follows:

    • Age 18 + years
    • History of chronic low back pain unresponsive to nonoperative care (including physical therapy and anti-inflammatory medication) for longer than 6 months of at least 5 on VAS
    • No surgical interventions within the last 3 months
    • Back pain more than leg pain which is commonly exacerbated by sitting
    • Pain reproduction present on provocative discography in degenerated disc but not in control discs
    • Disc height at least 50% of adjacent control disc
    • Evidence of single level degenerative disc disease or two level disease without evidence of additional degenerative changes in other disc spaces on MRI

Exclusion Criteria:

  • The exclusion criteria are :

    • Evidence of compressive radiculopathy with predominant leg pain
    • Nucleus pulposus herniation on the MRI
    • Disc bulges > 5 mm
    • Prior lumbar surgery of any kind
    • Presence of concordant cervical or thoracic pain
    • Symptoms or signs of the lumbar canal stenosis
    • Evidence of structural abnormality at the symptomatic level like spondylolisthesis
    • Chronic severe conditions such as rheumatoid arthritis and fibromyalgia
    • Patients with pending workers compensation claim, litigation or disability income remuneration
    • Psychological issues by exam or history
    • Beck Depression Inventory (BDI) >20
    • Pregnancy
    • Systemic infection or localized infection at the anticipated entry needle site
    • Allergies to contrast media or to any medication to be used in the procedure
    • Traumatic spinal fracture
    • History of coagulopathy, unexplained bleeding
    • Progressive neurological deficits
    • History of opioid abuse
    • Presence of free disc fragments on MRI
    • More than 2 discs degenerated on MRI
    • Immunosuppression (eg. AIDS, cancer, diabetes, other surgery within last 3 months)
    • Smoking
    • BMI (body mass index) >30 kg/m2
    • Subject unwilling to consent to the study
    • Participation in another investigation within 30 days of signing informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intradiscal Biacuplasty

On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.

Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.

Adjustment in dosage form, frequency and or duration.
Other Names:
  • Intradiscal Biacuplasty Active Comparator
interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
Other Names:
  • Sham: Placebo Comparator
Placebo Comparator: Sham

Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.

Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.

The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB.

Adjustment in dosage form, frequency and or duration.
Other Names:
  • Intradiscal Biacuplasty Active Comparator
interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
Other Names:
  • Sham: Placebo Comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Function
Time Frame: 6 months

Physical function as measured by the Short Form (36) Health Survey questionnaire physical function component.

Scale range for physical function component: 0 (minimum: worse outcome) to 100 (maximum: best outcome).

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain
Time Frame: 6 months
Pain level as measured by the Numerical Rating Scale. Scale range: 0 (minimum: best outcome) to 10 (maximum: worse outcome)
6 months
Disability
Time Frame: 6 months
Disability as measured by the Oswestry Disability Index. Scale range: 0 (minimum: best outcome) to 100 (maximum: worst outcome)
6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid Usage
Time Frame: 6 months
Patient reported Opioid usage (converted to morphine equivalents)
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Leonardo Kapural, MD, Center for Clinical Research
  • Principal Investigator: Bruce Vrooman, M.D., The Cleveland Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2007

Primary Completion (Actual)

September 1, 2012

Study Completion (Actual)

September 1, 2012

Study Registration Dates

First Submitted

September 9, 2008

First Submitted That Met QC Criteria

September 9, 2008

First Posted (Estimate)

September 10, 2008

Study Record Updates

Last Update Posted (Estimate)

January 8, 2014

Last Update Submitted That Met QC Criteria

November 20, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB 07-594

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lower Back Pain

Clinical Trials on The Transdiscal Radiofrequency Annuloplasty

3
Subscribe